Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.
作者信息
Woyach J A, Lozanski G, Ruppert A S, Lozanski A, Blum K A, Jones J A, Flynn J M, Johnson A J, Grever M R, Heerema N A, Byrd J C
出版信息
Leukemia. 2012 Jun;26(6):1442-4. doi: 10.1038/leu.2011.375. Epub 2012 Jan 13.
Abstract
摘要
相似文献
1
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.用黄酮哌醇治疗复发或难治性慢性淋巴细胞白血病患者的结果：基因特征的影响。
Leukemia. 2012 Jun;26(6):1442-4. doi: 10.1038/leu.2011.375. Epub 2012 Jan 13.
2
Flavopiridol in the treatment of chronic lymphocytic leukemia.黄酮哌酯治疗慢性淋巴细胞白血病。
Curr Opin Oncol. 2007 Nov;19(6):573-8. doi: 10.1097/CCO.0b013e3282efb9da.
3
Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway.慢性淋巴细胞白血病与癌症治疗耐药性：p53 通路的作用
Cell Cycle. 2008 Dec 15;7(24):3810-4. doi: 10.4161/cc.7.24.7245. Epub 2008 Dec 21.
4
Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.慢性淋巴细胞白血病中p53功能障碍与TP53和ATM缺失之间的不完全相关性。
Leukemia. 2006 Apr;20(4):737-40. doi: 10.1038/sj.leu.2404120.
5
Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.残留 ATM 等位基因的突变状态是慢性淋巴细胞白血病伴 11q 缺失患者细胞对化疗反应及生存情况的重要决定因素。
J Clin Oncol. 2007 Dec 1;25(34):5448-57. doi: 10.1200/JCO.2007.11.2649. Epub 2007 Oct 29.
6
The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.潜在的抗癌药物PK11195可诱导慢性淋巴细胞白血病细胞凋亡，且与p53和ATM状态无关。
Haematologica. 2007 Dec;92(12):1631-8. doi: 10.3324/haematol.11194.
7
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.对于接受基于伊布替尼方案治疗的复发或难治性慢性淋巴细胞白血病患者，复杂核型比17号染色体短臂缺失（del(17p)）更能预示不良预后。
Cancer. 2015 Oct 15;121(20):3612-21. doi: 10.1002/cncr.29566. Epub 2015 Jul 20.
8
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.伊布替尼用于既往未治疗及复发或难治的伴有TP53畸变的慢性淋巴细胞白血病：一项2期单臂试验
Lancet Oncol. 2015 Feb;16(2):169-76. doi: 10.1016/S1470-2045(14)71182-9. Epub 2014 Dec 31.
9
Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.ATM基因的突变会导致B细胞慢性淋巴细胞白血病患者的总生存期和无治疗生存期受损，且这一情况与IGVH突变状态无关。
Blood. 2005 Nov 1;106(9):3175-82. doi: 10.1182/blood-2004-11-4516. Epub 2005 Jul 12.
10
A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.一种使用依托泊苷加Nutlin-3a的新型功能检测方法可检测并区分慢性淋巴细胞白血病（CLL）中的ATM和TP53突变。
Leukemia. 2008 Jul;22(7):1456-9. doi: 10.1038/sj.leu.2405092. Epub 2008 Jan 17.
引用本文的文献
1
Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia.慢性淋巴细胞白血病诊断时存在 IGHV 突变和细胞遗传学复杂性的易位的预后意义。
Haematologica. 2021 Jun 1;106(6):1608-1615. doi: 10.3324/haematol.2018.212571.
2
Prognostic Factors in the Era of Targeted Therapies in CLL.CLL 靶向治疗时代的预后因素。
Curr Hematol Malig Rep. 2018 Apr;13(2):78-90. doi: 10.1007/s11899-018-0439-9.
3
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.伊布替尼单药治疗初治和复发/难治性慢性淋巴细胞白血病：5 年经验。
Blood. 2018 Apr 26;131(17):1910-1919. doi: 10.1182/blood-2017-10-810044. Epub 2018 Feb 2.
4
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of deletions.伴有复杂核型的慢性淋巴细胞白血病患者即使没有缺失也显示出不良预后。
Oncotarget. 2017 Apr 21;8(33):54297-54303. doi: 10.18632/oncotarget.17350. eCollection 2017 Aug 15.
5
Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.通过使用抗心绞痛药物哌克昔林靶向喜树碱来消除基质微环境中的慢性淋巴细胞白血病细胞。
Oncogene. 2016 Oct 27;35(43):5663-5673. doi: 10.1038/onc.2016.103. Epub 2016 Apr 11.
6
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.对于接受基于伊布替尼方案治疗的复发或难治性慢性淋巴细胞白血病患者，复杂核型比17号染色体短臂缺失（del(17p)）更能预示不良预后。
Cancer. 2015 Oct 15;121(20):3612-21. doi: 10.1002/cncr.29566. Epub 2015 Jul 20.
7
The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells.BAFF受体TACI通过调节性B细胞和慢性淋巴细胞白血病B细胞控制白细胞介素-10的产生。
Leukemia. 2016 Jan;30(1):163-72. doi: 10.1038/leu.2015.174. Epub 2015 Jul 3.
8
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.CDK9激酶活性和Mcl-1稳定性的上调导致白血病对细胞周期蛋白依赖性激酶抑制剂产生获得性耐药。
Oncotarget. 2015 Feb 20;6(5):2667-79. doi: 10.18632/oncotarget.2096.
9
Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?慢性淋巴细胞白血病中的移植：在新型靶向治疗时代它仍然重要吗？
Hematol Oncol Clin North Am. 2014 Dec;28(6):1055-71. doi: 10.1016/j.hoc.2014.08.005. Epub 2014 Sep 26.
10
Highlights of the Latest Advances in Research on CDK Inhibitors.细胞周期蛋白依赖性激酶（CDK）抑制剂研究的最新进展亮点
Cancers (Basel). 2014 Oct 27;6(4):2224-42. doi: 10.3390/cancers6042224.
本文引用的文献
1
TP53 mutation and survival in chronic lymphocytic leukemia.TP53 突变与慢性淋巴细胞白血病的生存。
J Clin Oncol. 2010 Oct 10;28(29):4473-9. doi: 10.1200/JCO.2009.27.8762. Epub 2010 Aug 9.
2
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.黄酮哌啶醇用于复发慢性淋巴细胞白血病的II期研究表明，其在基因高危疾病中具有高缓解率。
J Clin Oncol. 2009 Dec 10;27(35):6012-8. doi: 10.1200/JCO.2009.22.6944. Epub 2009 Oct 13.
3
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.TP53突变在慢性淋巴细胞白血病中的预后价值独立于17p13缺失：对总生存期和化疗难治性的影响
Clin Cancer Res. 2009 Feb 1;15(3):995-1004. doi: 10.1158/1078-0432.CCR-08-1630.
4
Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival.慢性淋巴细胞白血病中的克隆进化：获得与未突变VH相关的高危基因组畸变、对治疗的抗性及生存期短。
Haematologica. 2007 Sep;92(9):1242-5. doi: 10.3324/haematol.10720. Epub 2007 Aug 1.
5
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.未经治疗的早期慢性淋巴细胞白血病患者长期随访期间克隆进化的前瞻性评估。
J Clin Oncol. 2006 Oct 1;24(28):4634-41. doi: 10.1200/JCO.2006.06.9492.
6
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.使用药理学推导方案给药的黄酮哌醇在难治性、遗传高风险慢性淋巴细胞白血病中具有显著的临床疗效。
Blood. 2007 Jan 15;109(2):399-404. doi: 10.1182/blood-2006-05-020735. Epub 2006 Sep 26.
7
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.选择高风险基因特征可预测慢性淋巴细胞白血病患者接受氟达拉滨和利妥昔单抗化学免疫治疗后疾病进展更早：风险适应性治疗的依据
J Clin Oncol. 2006 Jan 20;24(3):437-43. doi: 10.1200/JCO.2005.03.1021. Epub 2005 Dec 12.
8
Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.ATM基因的突变会导致B细胞慢性淋巴细胞白血病患者的总生存期和无治疗生存期受损，且这一情况与IGVH突变状态无关。
Blood. 2005 Nov 1;106(9):3175-82. doi: 10.1182/blood-2004-11-4516. Epub 2005 Jul 12.
9
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.黄酮哌醇对转录的抑制作用：慢性淋巴细胞白血病细胞死亡机制
Blood. 2005 Oct 1;106(7):2513-9. doi: 10.1182/blood-2005-04-1678. Epub 2005 Jun 21.
10
Genomic aberrations and survival in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的基因组畸变与生存情况
N Engl J Med. 2000 Dec 28;343(26):1910-6. doi: 10.1056/NEJM200012283432602.
Zotero 插件